BIOMAT Database Logo BIOMAT Database Logo

[Treatment options for serious infections caused by vancomycin-resistant enterococci]. 2015

Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Deutsches Zentrum für Infektionsforschung (DZIF) Heidelberg, Universitätsklinikum Heidelberg.

Complicated infections caused by vancomycin-resistant enterococci (VRE) represent a therapeutic challenge, since adequate treatment options are limited and antibiotic resistance to the available agents has already been described. The most frequently used antibiotic in VRE treatment is linezolid. Tigecycline is an alternative to linezolid, however, clinical data for severe infections such as sepsis or endocarditis are scarce. Daptomycin on the one hand is an option but has not yet been approved for the treatment of enterococcal infections in Germany on the other hand. The present review critically evaluates the clinical significance of the antibiotics in question for VRE therapy based on existing data.

UI MeSH Term Description Entries
D008911 Minocycline A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections. Akamin,Akne-Puren,Aknemin,Aknin-Mino,Aknosan,Apo-Minocycline,Arestin,Blemix,Cyclomin,Cyclops,Dentomycin,Dynacin,Icht-Oral,Klinomycin,Lederderm,Mestacine,Minakne,Mino-Wolff,Minocin,Minocin MR,Minoclir,Minocycline Hydrochloride,Minocycline Monohydrochloride,Minocycline, (4R-(4 alpha,4a beta,5a beta,12a beta))-Isomer,Minolis,Minomycin,Minoplus,Minotab,Minox 50,Mynocine,Akne Puren,Aknin Mino,Apo Minocycline,Hydrochloride, Minocycline,Icht Oral,Mino Wolff,Monohydrochloride, Minocycline
D004755 Enterobacteriaceae A family of gram-negative, facultatively anaerobic, rod-shaped bacteria that do not form endospores. Its organisms are distributed worldwide with some being saprophytes and others being plant and animal parasites. Many species are of considerable economic importance due to their pathogenic effects on agriculture and livestock. Coliform Bacilli,Enterobacteria,Ewingella,Leclercia,Paracolobactrum,Sodalis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069349 Linezolid An oxazolidinone and acetamide derived ANTI-BACTERIAL AGENT and PROTEIN SYNTHESIS INHIBITOR that is used in the treatment of GRAM-POSITIVE BACTERIAL INFECTIONS of the skin and respiratory tract. Linezolide,N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide,PNU-100766,U 100766,U-100766,Zyvox,100766, U,PNU 100766,PNU100766,U100766
D000078304 Tigecycline A tetracycline derivative that acts as a protein synthesis inhibitor. It is used as an antibacterial agent for the systemic treatment of complicated skin and intra-abdominal infections. It is also used for the treatment of community-acquired pneumonia. 9-(tert-Butylglycylamido)minocycline,GAR 936,GAR-936,TBG-MINO,Tygacil,GAR936
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D016908 Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method. Bacterial Infections, Gram-Positive,Infections, Gram-Positive Bacterial,Bacterial Infection, Gram-Positive,Bacterial Infections, Gram Positive,Gram Positive Bacterial Infections,Gram-Positive Bacterial Infection,Infection, Gram-Positive Bacterial,Infections, Gram Positive Bacterial
D017576 Daptomycin A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA. Cubicin,Daptomycin, 9-L beta-Aspartic Acid,Deptomycin,LY-146032,Daptomycin, 9 L beta Aspartic Acid,LY 146032,LY146032

Related Publications

Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Therapeutic options for infections due to vancomycin-resistant enterococci.
April 2009, Expert opinion on pharmacotherapy,
Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci.
October 2021, Pharmacy (Basel, Switzerland),
Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Economic burden of nosocomial infections caused by vancomycin-resistant enterococci.
January 2018, Antimicrobial resistance and infection control,
Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.
December 2005, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Therapeutic Options for Infections due to vanB Genotype Vancomycin-Resistant Enterococci.
April 2021, Microbial drug resistance (Larchmont, N.Y.),
Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Treatment options for vancomycin-resistant enterococcal infections.
January 2002, Drugs,
Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci.
September 1999, The Journal of antimicrobial chemotherapy,
Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Blossoming vancomycin-resistant enterococci infections.
December 2017, The Journal of hospital infection,
Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
February 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Nico T Mutters, and Guido Werner, and Evelina Tacconelli, and Alexander Mischnik
Treatment of infections caused by highly resistant enterococci.
May 1997, International journal of antimicrobial agents,
Copied contents to your clipboard!